Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists. Wu X-S, Wang R, Xing Y-L, Xue X-Q, Zhang Y, Lu Y-Z, Song Y, Luo X-Y, Wu C, Zhou Y-L, et al. Acta Pharmacol Sin. 2016 Jul 4. PMID: 27374490. Abstract CommentRecommendBookmarkWatch